Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Mechanisms Underlying Asthma Exacerbations Prevented and Persistent With Immune-Based Therapy: A Systems Approach Phase 1 (ICAC-29)

NCT02502890 is registered in ClinicalTrials.gov with National Institute of Allergy and Infectious Diseases (NIAID) as lead sponsor.

NCT NCT02502890
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02502890 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Mechanisms Underlying Asthma Exacerbations Prevented and Persistent With Immune-Based Therapy: A Systems Approach Phase 1 (ICAC-29)
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Phase
Observational
Overall status
Completed
Start date
October 31, 2015
Completion date
January 31, 2017
Enrollment
208 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

asthma